Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockBusiness Wire • 12/11/24
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx ConferenceBusiness Wire • 11/26/24
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: AnalystBenzinga • 11/19/24
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association ConferenceBusiness Wire • 11/18/24
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science SessionsBusiness Wire • 11/12/24
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare ConferenceBusiness Wire • 11/08/24
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent ProgressBusiness Wire • 11/07/24
Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory MovesSeeking Alpha • 09/19/24
RCKT Completes Enrollment in Rare Heart Disease Study, Stock RisesZacks Investment Research • 09/18/24
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon DiseaseBusiness Wire • 09/17/24
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of DirectorsBusiness Wire • 09/10/24
Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent ProgressBusiness Wire • 08/05/24
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)Business Wire • 06/28/24
Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?Zacks Investment Research • 06/05/24
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic CardiomyopathyBusiness Wire • 05/29/24
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)Business Wire • 05/10/24